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During the past two decades, the diagnosis and management of patients with
benign prostatic hyperplasia (BPH) has dramatically changed. A range of options
including pharmacological therapies, device therapies and new surgical procedures
have emerged, and many of these new technologies have become available for the
treatment of BPH.1,2 However, these new therapeutic modalities have been
accompanied by controversy about the optimal strategies for treatment of BPH,
and they leave a great deal of room for the personal opinions of individual
physicians in the choice of treatment for patients with BPH. Despite several
clinical practice guidelines suggesting optimal frameworks for the diagnosis and
management of patients with BPH,3-9 there is a paucity of literature providing
evidence from randomized clinical trials as a basis for preferred management
strategies. Therefore, there are still arguments about applying these guidelines to
the practical treatment of individual patients.5 In Asian populations, there is an
another hurdle in applying these guidelines directly to the practical treatment of
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Purpose: In Korea, there was no specific guidelines for the management of benign prostatic hyperplasia (BPH).
We reviewed the practice patterns of Korean urologists in the management of BPH and aimed to describe the need
to develop specific guidelines. Materials and Methods: A probability sample was taken from the Korean
Urological Association Registry of Physicians, and a structured questionnaire, that explored practice patterns in the
management of BPH, was mailed to a random sample of 251 Korean urologists. Results: For the initial evaluation
of BPH, most urologists routinely performed prostatic specific antigen (PSA) (96.4%), digital rectal exam (94.4%),
international prostate symptom score (IPSS) (83.2%) and transrectal ultrasound (79.2%). Symptom assessment
(36.4%) followed by transrectal ultrasound of prostate (TRUS) (20.0%) was considered as the most important
diagnostic examination affecting the decision about individual treatment options. Almost all urologists (92.2%)
chose medical treatment as the first-line treatment option for uncomplicated BPH with moderate symptoms. Of the
respondents, 57.2% had prescribed alpha blocker and 41.6% alpha blocker plus 5-alpha reductase inhibitors as the
medical treatment option for BPH. The prescription of 5-ARIs was dependent on the size of the prostate and the
severity of symptoms. Conclusion: The results of our current survey provide useful insight into variations in the
clinical practice of Korean urologists. They also indicate the need to develop further practical guidelines based on solid
clinical data and to ensure that these guidelines are widely promoted and accepted by the urological community.
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INTRODUCTION
patients with BPH: in Asian men, the clinical characteri-
stics related to BPH are different from those of BPH patients
in Western populations. For example, Asian men have a
similar incidence of lower urinary tract symptoms (LUTS)
compared with men in the Western hemisphere, despite
having a smaller average prostate volume and lower serum
prostatic specific antigen (PSA) level.10,11 The current
practical patterns in the management of patients with BPH
may provide useful insights for setting up specific gui-
delines that include consideration of the clinical characteri-
stics of the Asian population. To define the current spec-
trum of practice of Korean urologists for management of
BPH, we performed a nationwide survey of the current
strategies used by Korean urologists for diagnosis and
management of patients with BPH.
We obtained a probability sample (n = 448) of Korean
urologists from the Korean Urological Association (KUA)
Registry of Physicians and selected 320 participants who
were informed of the purpose of the survey and agreed to be
enrolled before the survey began. Eligibility criteria required
that participants should be urologists not in residency
training and in active practice at least 20 hours per week. 
The survey was conducted from May 2007. It was based
on a structured questionnaire delivered via mail. Partici-
pants received the survey instrument, which consisted of a
cover letter that identified the author and described the
purpose of the survey and the survey questionnaire itself.
The questionnaire was developed by the authors of this
paper. The survey instrument was also reviewed and revised
by additional experts and pretested for clarity and conve-
nience for answering. The survey questionnaire was divided
into two parts. The physician’s preference in nonmedical
therapy for BPH and a subjective estimation of the changes
in treatment pattern related to patients with BPH were
collected through Part 1 of the questionnaire (6 separate
items). Part 2 of the questionnaire comprised 15 separate
items related to the diagnosis and management of patients
with BPH. It consisted of the practical view and patterns of
diagnostic procedures, strategy for medication, and the
individual physician’s preference for medical therapy.
Student’s t-test was done to determine the differences of
practice patterns between the urologists in private clinics
and general hospitals.
A total of 251 completed questionnaires were returned by
urologists. The consent rate in the survey was 71.4% (80.2%
in private clinics, 59.7% in general hospitals, respectively),
and the compliance rate for the 320 urologists who initially
agreed to participate was 78.4%.
Initial evaluation of men with suspected BPH 
Fig. 1 shows the symptoms that are frequently complained
of by patients with suspected BPH. Almost all patients
complained of voiding difficulties such as nocturia (98.8%),
weak stream (96.8%), post voiding residual urine sense
(95.6%) and daytime frequency (51.2%) while the incidence
of the terminal dribbling (0.4%) was extremely low. For
initial diagnostic assessments, the most frequently used
tests were serum PSA evaluation (96.4%) and DRE (94.4%),
and 91.6% of total respondents believed that the use of
PSA in the initial evaluation of BPH had increased in Korea
during the past decade. Symptom assessment, uroflow-
metry, DRE and residual urine volume were frequently
used more in general hospital rather than in private clinic
as the initial evaluation of BPH (Table 1). 
Monitoring of patients with BPH 
Table 1 lists various examinations and tests that were
routinely performed during the follow-up period for patients
with BPH. More than half the respondents (51.2%) reported
that they routinely performed repeated checks of the symp-
tom score during the follow-up period. The preference for
uroflowmetry (38%), serum PSA level (36%), DRE (35.2%)
and post voiding residual urine measurement (30.8%) were
similar. The preference for IPSS and uroflowmetry was
higher for urologists in general hospitals, while urologists
in private clinics performed DRE most frequently (48%)
(p < 0.05). 
Management pattern of patients with BPH 
As seen in Fig. 2, 92.2% of respondents replied that they
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MATERIALS AND METHODS 
Fig. 1. Common symptoms that are frequently complained by patients with
benign prostatic hyperplasia.
RESULTS
chose medical treatment as the initial management option
for patients with BPH. Among 137 urologists who had
experience of BPH-related surgery, 81% of respondents
reported that they performed transurethral resection of the
prostate (TURP) in at least one case during the past 12
months, while 25.5%, 22.4% and 15.3% of respondents
performed open prostatectomy, photoselective vaporization
of the prostate (PVP) and transurethral needle ablation
(TUNA), respectively (Fig. 2). There was a significant dif-
ference in the use of nonmedical treatment for BPH between
urologists in general hospitals and private clinics. Most
common nonmedical treatment option was TURP among
urologists in general hospitals (98%) while 38.5% for uro-
logists in private clinics (p < 0.05). However, laser ablation
was more common nonmedical treatment option for urolo-
gists in private clinics than that in general hospitals (33.3%
vs. 19.5%, respectively, p < 0.05). 
Of the pharmacological options, almost all urologists
reported that they prescribed alpha blocker in the manage-
ment of patients with BPH, while 5-ARIs were used less
frequently. Of the respondents, 57.2% had prescribed alpha
blocker as the primary treatment, and 41.6% prescribed
alpha blocker with 5-ARIs as the primary treatment. Only
0.4% of the respondents preferred 5-ARI monotherapy as
the initial treatment option for pharmacotherapy (Fig. 3).
There was no significant difference in the medical treat-
ment regimen between urologists in general hospitals and
in private clinics. 
Urologist views on treatment preference 
The judgment of severity of BPH is entirely individual
urologists’ estimation, but the proportion of combination
therapy (alpha blocker with 5-ARIs) increased with the
estimated severity of BPH. The proportion of alpha blocker
monotherapy decreased from 77.8% in mild BPH to 21.9%
in severe BPH, while the proportion of combination therapy
increased in severe BPH (19.5% to 75.8%). Among the
factors that were thought to be important when choosing
the prescribed drugs were rapid relief of the symptoms
(98.8%), the severity of BPH (85.2%), compliance of
patients (80.0%) and adverse effects of the drug (78.8%)
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Table 1. The Incidence of the Diagnostic Test for Patients with BPH as the Initial Evaluation and Follow Up 
Evaluation (%)
Initial evaluation Follow up evaluation
(multiple choice) (multiple choice)
General hospital Private clinic General hospital Private clinic 
(n = 102) (n = 149) (n = 102) (n = 149)
Symptoms assessment (IPSS) 98.0* 73.3* 68.0* 40.0*
Uroflowmetry 90.0* 50.0* 61.0* 22.7*
PSA 96.1 96.7 35.0 36.7
DRE 94.4* 35.2* 16.0* 48.0*
Residual urine volume 89.0* 55.3* 44.0* 22.0*
TRUS 89.0 72.7 8.0* 26.0*
Pressure-flow study 24.0 16.7 7.0 6.0
etc 4.0 2.1 2.0 6.6
BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; PSA, prostatic specific antigen; DRE, digital rectal 
examination; TRUS, transtrectal ultrasound of prostate.
*p < 0.05 by Student’s t-test.
Fig. 2. The choice of non pharmacological therapy during the preceding 12
months (multiple choice). TURP, transurethral resection of the prostate; TUNA,
transurethral needle ablation; TUDP, transurethral balloon dilation of the
prostate.
Fig. 3. The initial choices of pharmacological therapy for the newly diagnosed
BPH patients. CAM, complimentary alternative medicine; BPH, benign prostatic
hyperplasia.
(Fig. 4). However, there was no significant difference in
main concerns related to the decision of medical treatments
between urologists in general hospitals and private clinics. 
The evaluation and management of BPH has changed
markedly, and these changes include the development of
guidelines for investigation of BPH, the use of standard
symptom scores and quality of life assessment, and the
introduction of new medical therapies and technology.
Despite the voluminous literature on BPH, many uncer-
tainties still exist regarding the appropriate evaluation and
management of individuals. Although several clinical prac-
tice guidelines have addressed the optimal treatment of
men with BPH, there remain wide variations in patterns of
practice. There are, in fact, several differences in the recom-
mendations of the AUA guidelines and the EAU guide-
lines, which are widely accepted as the standard references
for the management of patients with BPH.3,6 The differen-
ces in the recommendations of the guidelines may have
originated not only from the difference in the patients’
demographics and genetic factors but also from the medi-
cal insurance system, the accessibility of hospitals, man-
power issues and cultural differences. There are no country-
specific practice guidelines for Korea. Although the AUA
and EAU guidelines are accepted in Korea as the two
alternative choices for the management of patients with
BPH, there is a paucity of literature concerning whether
they really affect patient evaluation and management.
Considering these points, the current report may provide
some indication of the influence of the international gui-
delines on Korean urologists. DRE, assessment of symp-
toms score and PSA are the common recommendations of
most of the international guidelines.5 In this survey, it was
revealed that these examinations and evaluations are
routinely performed by most of the urologists in Korea.
We found that the preference for TRUS, uroflowmetry and
post voiding residual urine measurement as the routine
monitoring for BPH was significantly higher compared
with the urologists’ preference in other countries.12-14 TRUS
is an optional test in both AUA and EAU guidelines, while
uroflowmetry and postvoiding residual urine measurement
are recommended only in the EAU guidelines.3,6 There
might be multiple factors affecting the urologists’ prefer-
ence for these additional tests in evaluation of BPH. The
authors believe that the public medical insurance system in
Korea might be one of the most important factors. Korea is
one of the advanced countries that have a well-established
public medical insurance system, meaning that medical
costs are very much cheaper than in other countries. For
example, the medical fee for DRE in Korea is only three
US dollars, and indeed the authors of this survey usually
do not charge the DRE fee to patients. On the other hand,
TRUS and uroflowmetry are relatively expensive, and the
public insurance does not cover them. Although this is not
the only possible explanation of the difference in the
preferences of urologists in Korea, it is possible that these
specific socioeconomic factors in Korea could affect the
pattern of urologists’ preferences in BPH evaluation prac-
tice. It was one of the important points of this survey that
we could obtain information about the patterns of monitor-
ing of patients with BPH by urologists. Despite numerous
reports about the initial evaluation of BPH, there is little
literature about the patterns of follow-up.
The surgical treatment of BPH has gradually decreased
in Korea during recent decades. At the same time, the pro-
portion of patients with BPH given medical treatment
increased.10 We also found through this survey that most
urologists believe that the incidence of TURP and other
BPH-related surgery has given way to medical treatment
as the optimal treatment for BPH.
The results of our current survey provide useful insights
into variations in the clinical practice of Korean urologists.
They also indicate the need to develop further practical
guidelines, based on solid clinical data, and to ensure that
these guidelines are widely promoted and accepted by the
urological community. Further information on the pre-
ferences of patients themselves will help to advance the
effectiveness of BPH treatment. Moreover, country-specific
guidelines that take into consideration the characteristics of
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Fig. 4. Main concerns of the urologists that affect the initial treatment of the
patients with BPH. BPH, benign prostatic hyperplasias; AUR, acute urinary
retention.
DISCUSSION
Korean men and the specific socioeconomic status of the
individual country are needed for the advancement of
evaluation and management of patients with BPH.
We would like to thank all participating urologists of the
Korean Urological Association for their cooperation in this
survey. 
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